| Literature DB >> 31360211 |
Oussama Bekkouch1, Mohamed Harnafi1, Ilham Touiss1, Saloua Khatib1, Hicham Harnafi1, Chakib Alem2, Souliman Amrani1.
Abstract
Over the past decades, cardiovascular diseases have become the leading cause of death all over the world, and among these diseases there is atherosclerosis caused mainly by an increase in plasmatic cholesterol levels and by strong oxidation caused by free radicals. For these reasons and others, we explored in this report the hypolipidemic and the antioxidant effects of Zingiber officinale crude aqueous and methanolic extract. The hypolipidemic study was carried out in high-fat-fed mice model. Animals were subdivided into four groups and were orally treated with the aqueous extract once daily for twelve weeks at two doses: 250 and 500 mg/Kg. During the treatment, the body weight, total cholesterol, triglycerides, and high-density lipoproteins have been defined every four weeks. The antioxidant activity has been studied using radical scavenging activity, β-carotene bleaching, reducing power assay, and the TBARs tests. The daily oral administration of the extracts for twelve weeks significantly improved the lipid profile in a dose-dependent manner, from the first until the twelfth week, and also showed a significant antioxidant effect. These findings may be potentially contributive to the validation of the medicinal use of Z. officinale to treat hyperlipidemia and cardiovascular complications.Entities:
Year: 2019 PMID: 31360211 PMCID: PMC6652026 DOI: 10.1155/2019/9734390
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Polyphenols and flavonoid contents and antioxidant activities (RSA and β-carotene) of Z. officinale.
|
| Standards | |||
|---|---|---|---|---|
| ZOAE | ZOMF | AA | BHA | |
| Polyphenols (mg eq gallic acid/g Ext) | 15.34 ± 2.21 | 27.12 ± 3.08 | - | - |
| Flavonoids (mg eq quercetin/g Ext) | 4.20 ± 1.23 | 11.67 ± 2.86 | - | - |
| RSA (IC50 ( | 23.30 ± 1.04b | 9.78 ± 0.33b | 1.83 ± 0.01a | - |
|
| 128.41 ± 9.85b | 71.55 ± 2.17b | - | 2.20 ± 0.05a |
All values were expressed as mean ± standard error of the mean; a: expressed as mg gallic acid equivalent/g of dry plant extract; b: expressed as mg quercetin equivalent/g of dry plant extract. a: p < 0.001; c: p < 0.05; b: p < 0.01; NS: not significant.
Figure 1Reducing power assay of Z. officinale extracts. Values are mean ± SEM; ZOAE: Z. officinale aqueous extract; ZOMF: Z. officinale methanolic fraction; AA: Ascorbic acid.
Figure 2Evaluation of lipid peroxidation by assaying thiobarbituric acid reactive substances (TBARs) of Z. officinale extracts. Values are mean ± SEM; Ox-LRP: oxidized lipoprotein-rich plasma. ZOAE: Z. officinale aqueous extract; ZOMF: Z. officinale methanolic fraction; BHA: Butylated hydroxyanisole. a: P < 0.001; (ZOAE, ZOMF and BHA vs. ox-LRP and ox-LRP vs. control).
Comparison of weight gain and food intake from the 4th week to the 12th week.
|
|
|
| ||||
|---|---|---|---|---|---|---|
| Weight (g) | Food intake (g/mouse/day) | Weight | Food intake (g/mouse/day) | Weight | Food intake (g/mouse/day) | |
| NCG | 25.2 ± 0.4 | 3.15 ± 0.08 | 25.8 ± 0.2 | 2.95 ± 0.10 | 26.1 ± 0.2 | 3.01 ± 0.12 |
| HCG | 32.5a ± 0.2 | 2.93 ± 0.11 | 33.3a ± 0.3 | 3.11 ± 0.06 | 34.8a ± 0.3 | 3.14 ± 0.08 |
| AETG 1 | 27.4b ± 0.2 | 3.02 ± 0.05 | 29.9c ± 0.2 | 2.99 ± 0.05 | 30.6c ± 0.2 | 2.92 ± 0.09 |
| AETG 2 | 27.0b ± 0.3 | 3.10 ± 0.09 | 28.5b ± 0.1 | 2.85 ± 0.10 | 29.1c ± 0.2 | 3.04 ± 0.11 |
| STG | 28.6c ± 0.4 | 2.98 ± 0.04 | 29.7c ± 0.2 | 3.07 ± 0.08 | 31.5NS ± 0.4 | 2.89 ± 0.03 |
Values are expressed as means ± SEM from ten mice in each lot. a: p < 0.001; c: p < 0.05; b: p < 0.01; NS: not significant.
Changes of plasma, total cholesterol, and triglycerides (mmol.L−1) in control and treated mice.
| 4th week | 8th week | 12th week | ||||
|---|---|---|---|---|---|---|
| TC | TG | TC | TG | TC | TG | |
| NCG | 2.10 ± 0.11 | 1.07 ± 0.06 | 2.35 ± 0.15 | 1.21 ± 0.05 | 2.51 ± 0.13 | 1.48 ± 0.08 |
| HCG | 4.62 ± 0,25a | 2.49 ± 0.13a | 4.78 ± 0.22a | 2.52 ± 0.12a | 4.97 ± 0.30a | 2.83 ± 0.10a |
| AETG dose 1 | 3.29 ± 0.19a | 2.25 ± 0.07NS | 3.77 ± 0.18b | 2.33 ± 0.1NS | 3.80 ± 0.12b | 2.45 ± 0.11c |
| AETG dose 2 | 2.36 ± 0.09a | 1.61 ± 0.04a | 2.42 ± 0.11a | 1.75 ± 0.07a | 2.55 ± 0.10a | 1.92 ± 0.08a |
| STG | 2.20 ± 0.05a | 1.93 ± 0.05a | 2.35 ± 0.08a | 2.03 ± 0.07b | 2.41 ± 0.11a | 2.20 ± 0.13b |
Values are expressed as means ± SEM from ten mice in each lot; TC: total cholesterol; TG: triglycerides. HCG compared with NCG. AETG and STG compared with HCG. a: p < 0.001; c: p < 0.05; b: p < 0.01; NS: not significant.
Changes of plasma HDL-C, LDL-C (mmol.l−1), and atherogenic index of plasma in control and treated mice.
| 4th week | 8th week | 12th week | |||||||
|---|---|---|---|---|---|---|---|---|---|
| HDL | LDL | AIP | HDL | LDL | AIP | HDL | LDL | AIP | |
| NCG | 1.41 ± 0.06 | 0.48 ± 0.08 | 0.49 | 1.45 ± 0.05 | 0.66 ± 0.07 | 0.62 | 1.43 ± 0.13 | 0.78 ± 0.04 | 0.76 |
| HCG | 1.02 ± 0,04a | 2.90 ± 0.13a | 2.79 | 0.88 ± 0.03a | 3.20 ± 0.11a | 3.43 | 0.91 ± 0.02a | 3.49 ± 0.14a | 4.46 |
| AETG dose 1 | 1.36 ± 0.05a | 1.49 ± 0.05a | 1.42 | 1.43 ± 0.08a | 1.87 ± 0.04a | 1.64 | 1.45 ± 0.05a | 1.86 ± 0.10a | 1.62 |
| AETG dose 2 | 1.42 ± 0.04a | 0.62 ± 0.06a | 0.66 | 1.49 ± 0.02a | 0.58 ± 0.09a | 0.62 | 1.55 ± 0.04a | 0.62 ± 0.08a | 0.65 |
| STG | 1.29 ± 0.03a | 0.53 ± 0.09a | 0.71 | 1.35 ± 0.06a | 0.59 ± 0.08a | 0.74 | 1.41± 0.06a | 0.56 ± 0.09a | 0.71 |
Values are expressed as means ± SEM from ten mice in each lot. TC: total cholesterol; TG: triglycerides; AI: atherogenic index. HCG compared with NCG. AETG and STG compared with HCG. a: p < 0.001; c: p < 0.05; b: p < 0.01; NS: not significant.
Comparison of LDL/HDL and TC/HDL ratios followed for twelve weeks.
| 4th week | 8th week | 12th week | ||||
|---|---|---|---|---|---|---|
| Ratio | LDL/HDL | TC/HDL | LDL/HDL | TC/HDL | LDL/HDL | TC/HDL |
| NCG | 0.34 | 1.49 | 0.45 | 1.62 | 0.54 | 1.75 |
| HCG | 2.37 | 3.79 | 2.96 | 4.43 | 3.83 | 5.46 |
| AETG1 | 1.08 | 2.42 | 1.30 | 2.63 | 1.28 | 2.62 |
| AETG2 | 0.43 | 1.66 | 0.38 | 1.62 | 0.40 | 1.64 |
| STG | 0.41 | 1.70 | 0.43 | 1.74 | 0.39 | 1.71 |
Figure 3Effects of ginger extracts and Atorvastatin on total liver cholesterol and triglycerides in mice (mg/g of the liver). Values are mean ± SEM from ten mice. a: p < 0.001; b: p <0.01.
Figure 4Changes on fecal total cholesterol excretion in regular and treated groups during 12 weeks (mg/g of feces).